^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/03/2021
Excerpt:
PD-L1 expression positive (≥50%)…squamous cell carcinoma…Preferred…cemiplimab-rwlc (category 1)
Source:
Title:
1438P - Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
Published date:
10/16/2023
Excerpt:
In EMPOWER-Lung 1, pts with ≥50% programmed cell death-ligand 1 (PD-L1) were randomized 1:1 to first-line (1L) cemiplimab monotherapy or platinum-doublet chemotherapy (chemo)....In EMPOWER-Lung 1, at median follow-up of 37.1 mo, for squamous pts treated with cemiplimab vs chemo, median overall survival (OS) was 22.7 vs 13.5 mo (HR: 0.51; 95% CI: 0.37, 0.69), and median progression-free survival (PFS) was 8.3 vs 5.9 mo (HR: 0.44; 95% CI: 0.32, 0.59). The objective response rate (ORR) was 43.9% vs 22.1%, and the median duration of response (DOR) was 16.0 mo (95% CI: 10.4, 33.0) vs 4.3 mo (95% CI: 4.2, 6.1), respectively.
Trial ID:
Title:
Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in >= 50% of tumour cells with no EGFR, ALK or ROS1 aberrations
Excerpt:
Libtayo® (cemiplimab) is now approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test with no EGFR, ALK, or ROS1 aberrations...
